VistaGen Therapeutics (VTGN) - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92840H2022
VistaGen Therapeutics Inc. (NASDAQ: VTGN) is a biopharmaceutical company that focuses on creating innovative solutions for individuals struggling with anxiety, depression, and other CNS disorders.
The company has an impressive pipeline consisting of six clinical stage product candidates, including pherines, PH94B nasal spray for social anxiety disorder, PH10 nasal spray for major depressive disorder, PH15 for cognition improvement, PH80 for menopausal hot flashes and migraine, PH284 for wasting syndrome Cachexia, and AV-101 for depression and neurological disorders.
Moreover, VistaGen Therapeutics has a strategic collaboration with EverInsight Therapeutics Inc. to develop treatments for ophthalmologic and CNS disorders. Founded in 1998 and headquartered in South San Francisco, California, the company is dedicated to revolutionizing mental health treatments. Visit their website at https://www.vistagen.com for more information.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
VTGN Stock Overview
| Market Cap in USD | 139m |
| Sector | Healthcare |
| Industry | Biotechnology |
| GiC SubIndustry | Biotechnology |
| TER | 0.00% |
| IPO / Inception | 2016-05-06 |
VTGN Stock Ratings
| Growth 5y | -3.52 |
| Fundamental | - |
| Dividend | - |
| Rel. Performance vs Sector | 0.90 |
| Analysts | 4.75/5 |
| Fair Price Momentum | 4.94 USD |
| Fair Price DCF | - |
VTGN Dividends
| Yield 12m | 0.00% |
| Yield on Cost 5y | 0.00% |
| Dividends CAGR 5y | 0.00% |
| Payout Consistency | 0.0% |
VTGN Growth Ratios
| Growth 12m | 13.10% |
| Growth Correlation 12m | 21% |
| Growth Correlation 3m | -7% |
| CAGR 5y | -32.30% |
| Sharpe Ratio 12m | 0.01 |
| Alpha vs SP500 12m | -11.33 |
| Beta vs SP500 5y weekly | 1.02 |
| ValueRay RSI | 49.12 |
| Volatility GJR Garch 1y | 325.15% |
| Price / SMA 50 | 0% |
| Price / SMA 200 | 5.79% |
| Current Volume | 194.4k |
| Average Volume 20d | 246.7k |
External Links for VTGN Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X (Twitter) • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of April 27, 2024, the stock is trading at USD 4.75 with a total of 194,425 shares traded.
Over the past week, the price has changed by -0.21%, over one month by +9.20%, over three months by -2.06% and over the past year by +16.00%.
According to ValueRays Forecast Model, VTGN VistaGen Therapeutics will be worth about 5.5 in April 2025. The stock is currently trading at 4.75. This means that the stock has a potential upside of +16%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 13 | 174 |
| Analysts Target Price | 12 | 153 |
| ValueRay Target Price | 5.5 | 16.0 |